Subclinical atherosclerosis in patients with undifferentiated connective tissue disease: comparison with rheumatoid arthritis
Authors:
- Georgios V. PapamichailGPGeorgios V. Papamichail
- Nikolaos A. GeorgiadisNGNikolaos A. Georgiadis
- Vasileios G. XydisVXVasileios G. Xydis
- Iro RaptiIRIro Rapti
- Christina A. KapsaliCKChristina A. Kapsali
- Athanasios KitsakosAKAthanasios Kitsakos
- Alexandros A. DrososADAlexandros A. Drosos
- Paraskevi V. VoulgariPVParaskevi V. Voulgari
- 23 March 2026
- journal article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (6) , 3057-3065
Abstract
To investigate the lipid profile and subclinical atherosclerosis in patients with undifferentiated connective tissue disease (UCTD), in comparison with rheumatoid arthritis (RA) and healthy individuals. This cross-sectional controlled study included 30 patients with UCTD, treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), 59 patients with RA receiving csDMARDs, and 31 age- and sex-matched healthy controls. All participants had no history or presence of coronary artery disease, hypertension, diabetes mellitus, dyslipidemia, thyroid disease, smoking, and none received diuretics, cholesterol-lowering drugs, or other agents affecting the lipid profile. Fasting serum lipid parameters such as total cholesterol (TC), triglycerides (TGL), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured in all patients and controls. Subclinical atherosclerosis was assessed by measuring carotid intima-media thickness (cIMT) using ultrasonography. UCTD patients exhibited significantly lower TC and HDL-C levels compared with controls (204.4 ± 43.0 mg/dL vs 238 ± 41.4 mg/dL, p < 0.004 and 50.6 ± 9.5 mg/dL vs 61.3 ± 13.3 mg/dL, p < 0.002 respectively). They also presented with increased cIMT compared to healthy controls (0.8 [0.6-1.5] mm vs 0.6 [0.5-0.7] mm, p < 0.001). No differences were observed in TGL and LDL-C among UCTD and healthy controls. RA patients demonstrated higher cIMT (in unadjusted analyses) and HDL-C compared to UCTD patients (0.9 [0.8-1.0] mm vs 0.8 [0.6-1.5] mm, p < 0.001 and 56.8 ± 15.2 mg/dL vs 50.6 ± 9.5 mg/dL, p < 0.004 respectively). However, after multivariable linear regression analysis adjusting for age, sex, ESR, and disease duration, disease type was not independently associated with cIMT (β = 0.02, 95% CI - 0.16 to 0.19; p = 0.86). Subclinical atherosclerosis was observed in both RA and UCTD patients compared with healthy controls. Although RA patients exhibited higher cIMT values in unadjusted analyses, disease type was not independently associated with cIMT after multivariable adjustment. These findings suggest that cumulative inflammatory burden rather than diagnostic category alone may contribute to vascular alterations. Prospective longitudinal studies are required to clarify cardiovascular risk evolution in UCTD. Key Points • Patients with UCTD exhibit subclinical atherosclerosis despite conventional immunosuppressive treatment. • RA patients show a greater burden of subclinical atherosclerosis compared with UCTD patients in unadjusted analyses. • Quantitative lipid levels partly explain cardiovascular risk in inflammatory rheumatic diseases, highlighting the role of endothelial dysfunction and immune-mediated mechanisms.Keywords
This publication has 47 references indexed in Scilit:
- Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled studyClinical Rheumatology, 2023
- The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational studyHeart and Vessels, 2022
- The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular riskRheumatology International, 2020
- Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2020
- Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High‐Density Lipoprotein–Enriched Serum in Rheumatoid ArthritisArthritis & Rheumatology, 2016
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by TofacitinibArthritis & Rheumatology, 2015
- Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta‐AnalysisArthritis & Rheumatology, 2014
- Lipid and Lipoprotein Levels and Trend in Rheumatoid Arthritis Compared to the General PopulationArthritis Care & Research, 2013
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportArthritis & Rheumatism, 2010
- Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritisArthritis & Rheumatism, 2006